source
- Samsung Biologics proposes $1.8B acquisition of PolyPeptide to enter fast-growing obesity peptide marketSamsung Biologics, a South Korean contract development and manufacturing organization, announced an offer to acquire Swiss CDMO PolyPeptide for CHF 1.46 billion (about $1.8 billion). PolyPeptide s…
- Novo Nordisk sues Eli Lilly over alleged misleading obesity drug adsNovo Nordisk filed a lawsuit in a New Jersey federal court accusing Eli Lilly of deceptive advertising for its GLP-1 obesity medicines. The action follows a cease-and-desist request that asked Lil…